Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14;14(1):44.
doi: 10.1038/s41408-024-01033-7.

Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century

Kari Hemminki  1   2 , Frantisek Zitricky  3 , Asta Försti  4   5 , Mika Kontro  6   7   8 , Bjorn T Gjertsen  9   10 , Marianne Tang Severinsen  11   12 , Gunnar Juliusson  13   14
Affiliations

Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century

Kari Hemminki et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

MK reports personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron, Jazz Pharmaceuticals, Novartis and Pfizer and research funding from AbbVie. BTG reports Stock and Other Ownership Interests: Kinn Therapeutics AS, Alden Cancer Therapy AS, Hà Biotech AS. Consulting or Advisory Role: Abbvie, Astellas Pharma, AstraZeneca AS, BerGenBio, Coegin Pharma, GreinDX, Immedica Pharma, Incyte, Laboratories Delbert, MSD (Norge) AS, Novartis, Otsuka. Speakers’ Bureau Company: Pfizer, Sanofi Genzyme, Oslo Cancer Cluster, Novartis. GJ reports advisory board attendance and lecturing for AbbVie, Astellas, and Servier, and research collaboration with Jazz Pharma and Novartis. The other authors declare no conflict.

Figures

Fig. 1
Fig. 1. Age-specific relative survival in AML In Sweden.
The panels show relative survival in Swedish men (A–C) and women (D–F) specifying 1-year (A, D), 5/1-year (B, E) and 5-year (C, F) survival. Shading shows 95%CIs. For the oldest patient data are incomplete and individual data points are shown with large circles.
See this image and copyright information in PMC

References

    1. Hemminki K, Hemminki J, Försti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia. 2023;37:854–63. doi: 10.1038/s41375-023-01852-w. - DOI - PMC - PubMed
    1. Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56. doi: 10.1038/s41408-020-0323-4. - DOI - PMC - PubMed
    1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi: 10.1182/blood.2022016867. - DOI - PubMed
    1. DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073–86. doi: 10.1016/S0140-6736(23)00108-3. - DOI - PubMed
    1. Kaplan ZLR, van Leeuwen N, Posthuma EFM, Visser O, Huls G, van de Loosdrecht AA, et al. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something. Leukemia. 2022;36:596–8. doi: 10.1038/s41375-021-01503-y. - DOI - PubMed

Publication types

MeSH terms